DOCSLIB.ORG

Multicenter, Single Arm, Phase II Trial on the Efficacy of Ortataxel in Recurrent Glioblastoma (2019) Journal of Neuro-Oncology, 142 (3), Pp

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Multicenter, Single Arm, Phase II Trial on the Efficacy of Ortataxel in Recurrent Glioblastoma (2019) Journal of Neuro-Oncology, 142 (3), Pp Documents Export Date: 21 Jan 2020 Search: AU-ID("Gaviani, Paola" 6506528764) 1) Silvani, A., De Simone, I., Fregoni, V., Biagioli, E., Marchioni, E., Caroli, M., Salmaggi, A., Pace, A., Torri, V., Gaviani, P., Quaquarini, E., Simonetti, G., Rulli, E., D’Incalci, M., Poli, D., Mariotti, E., Caramia, G., Gritti, A.P., Pacchetti, I., Zucchetti, M., Lanza, A., Basso, G., Bini, P., Berzero, G., Diamanti, L., Di Cristofori, A., Manzoni, A., Lanfranchi, G., Ardizzoia, A., Villani, V. Multicenter, single arm, phase II trial on the efficacy of ortataxel in recurrent glioblastoma (2019) Journal of Neuro-Oncology, 142 (3), pp. 455-462. 1) https://www.scopus.com/inward/record.uri?eid=2-s2.0-85061248819&doi=10.1007%2fs11060-019-03116-z&partnerID=40&md5=55ca05a12a766ded77ba791fd16b7b7c DOI: 10.1007/s11060-019-03116-z Document Type: Article Publication Stage: Final Source: Scopus 2) Simonetti, G., Sommariva, A., Lusignani, M., Anghileri, E., Ricci, C.B., Eoli, M., Fittipaldo, A.V., Gaviani, P., Moreschi, C., Togni, S., Tramacere, I., Silvani, A. Prospective observational study on the complications and tolerability of a peripherally inserted central catheter (PICC) in neuro-oncological patients (2019) Supportive Care in Cancer, . 2) https://www.scopus.com/inward/record.uri?eid=2-s2.0-85075206792&doi=10.1007%2fs00520-019-05128-x&partnerID=40&md5=5550a094872f579fb7bf84be2a261c33 DOI: 10.1007/s00520-019-05128-x Document Type: Article Publication Stage: Article in Press Source: Scopus 3) Simonetti, G., Terreni, M.R., DiMeco, F., Fariselli, L., Gaviani, P. Letter to the editor: lung metastasis in WHO grade I meningioma (2018) Neurological Sciences, 39 (10), pp. 1781-1783. Cited 1 time. 3) https://www.scopus.com/inward/record.uri?eid=2-s2.0-85047919670&doi=10.1007%2fs10072-018-3459-2&partnerID=40&md5=e845d49507e0699ad28f9965a2ac32d7 DOI: 10.1007/s10072-018-3459-2 Document Type: Letter Publication Stage: Final Source: Scopus 4) Rigamonti, A., Imbesi, F., Silvani, A., Gaviani, P., Agostoni, E., Porcu, L., De Simone, I., Torri, V., Salmaggi, A. Terms and conditions Privacy policy Copyright © 2020 Elsevier B.V. All rights reserved. Scopus® is a registered trademark of Elsevier B.V. Antiepileptic treatment and survival in newly diagnosed glioblastoma patients: Retrospective multicentre study in 285 Italian patients (2018) Journal of the Neurological Sciences, 390, pp. 14-19. Cited 1 time. 4) https://www.scopus.com/inward/record.uri?eid=2-s2.0-85045030387&doi=10.1016%2fj.jns.2018.04.004&partnerID=40&md5=9278d039124601e2b172ba214e3fd228 DOI: 10.1016/j.jns.2018.04.004 Document Type: Article Publication Stage: Final Source: Scopus 5) Mattei, L., Prada, F., Marchetti, M., Gaviani, P., DiMeco, F. Differentiating brain radionecrosis from tumour recurrence: a role for contrast-enhanced ultrasound? (2017) Acta Neurochirurgica, 159 (12), pp. 2405-2408. Cited 1 time. 5) https://www.scopus.com/inward/record.uri?eid=2-s2.0-85028970341&doi=10.1007%2fs00701-017-3306-x&partnerID=40&md5=858490abf1ea7e1f35e37e6dba772601 DOI: 10.1007/s00701-017-3306-x Document Type: Article Publication Stage: Final Source: Scopus 6) Simonetti, G., Silvani, A., Fariselli, L., Hottinger, A.F., Pesce, G.A., Prada, F., Gaviani, P. Extra central nervous system metastases from glioblastoma: a new possible trigger event? (2017) Neurological Sciences, 38 (10), pp. 1873-1875. 6) https://www.scopus.com/inward/record.uri?eid=2-s2.0-85021188547&doi=10.1007%2fs10072-017-3036-0&partnerID=40&md5=84f9e580c9056a90c5cf9a6e181e731e DOI: 10.1007/s10072-017-3036-0 Document Type: Article Publication Stage: Final Source: Scopus 7) Fariselli, L., Cuppini, L., Gaviani, P., Marchetti, M., Pinzi, V., Milanesi, I., Simonetti, G., Tramacere, I., DiMeco, F., Salmaggi, A., Silvani, A. Short course radiotherapy concomitant with temozolomide in GBM patients: A phase II study (2017) Tumori, 103 (5), pp. 457-463. Cited 1 time. 7) https://www.scopus.com/inward/record.uri?eid=2-s2.0-85031103457&doi=10.5301%2ftj.5000672&partnerID=40&md5=4b99b10db2cdca99ae0d0ab25d181acd DOI: 10.5301/tj.5000672 Document Type: Article Publication Stage: Final Source: Scopus Terms and conditions Privacy policy Copyright © 2020 Elsevier B.V. All rights reserved. Scopus® is a registered trademark of Elsevier B.V. 8) Rigamonti, A., Imbesi, F., Silvani, A., Grimod, G., Prone, V., Gaviani, P., Ardizzoia, A., Milanesi, I., Arienti, V., Agostoni, E., Di Meco, F., Salmaggi, A. Pattern of care and outcome in elderly patients with glioblastoma: Data in 151 patients from 3 Lombardia Hospitals (2017) Journal of the Neurological Sciences, 378, pp. 3-8. Cited 7 times. 8) https://www.scopus.com/inward/record.uri?eid=2-s2.0-85018525486&doi=10.1016%2fj.jns.2017.04.030&partnerID=40&md5=cb6e4cfb4401a60030921b72bade46be DOI: 10.1016/j.jns.2017.04.030 Document Type: Article Publication Stage: Final Source: Scopus 9) Simonetti, G., Gaviani, P., Lamperti, E., Innocenti, A., Botturi, A., Saini, M., Pollo, B., Silvani, A. A case of medulloblastoma in adult patient affected by anaplastic oligoastrocytoma (2016) Neurological Sciences, 37 (10), pp. 1727-1730. Cited 1 time. 9) https://www.scopus.com/inward/record.uri?eid=2-s2.0-84975266390&doi=10.1007%2fs10072-016-2640-8&partnerID=40&md5=405841ff616f5d3bfd2b1dc898d35995 DOI: 10.1007/s10072-016-2640-8 Document Type: Article Publication Stage: Final Source: Scopus 10) Corsini, E., Gaviani, P., Chiapparini, L., Lazzaroni, M., Ciusani, E., Bisogno, R., Silvani, A., Salmaggi, A., Bernardi, G. Intrathecal synthesis of onconeural antibodies in patients with paraneoplastic syndromes (2016) Journal of Neuroimmunology, 290, pp. 119-122. Cited 7 times. 10) https://www.scopus.com/inward/record.uri?eid=2-s2.0-84955167495&doi=10.1016%2fj.jneuroim.2015.11.016&partnerID=40&md5=9132cf538d0f0b0128d1d430ecc9c30a DOI: 10.1016/j.jneuroim.2015.11.016 Document Type: Article Publication Stage: Final Source: Scopus 11) Gaviani, P., Simonetti, G., Innocenti, A., Lamperti, E., Botturi, A., Silvani, A. Safety and efficacy of primary central nervous system lymphoma treatment in elderly population (2016) Neurological Sciences, 37 (1), pp. 131-133. Cited 2 times. 11) https://www.scopus.com/inward/record.uri?eid=2-s2.0-84955660678&doi=10.1007%2fs10072-015-2371-2&partnerID=40&md5=83dfca44a9d194ec665f4a4612cce4c4 DOI: 10.1007/s10072-015-2371-2 Document Type: Article Publication Stage: Final Terms and conditions Privacy policy Copyright © 2020 Elsevier B.V. All rights reserved. Scopus® is a registered trademark of Elsevier B.V. Source: Scopus 12) Simonetti, G., Gaviani, P., Botturi, A., Innocenti, A., Lamperti, E., Silvani, A. Clinical management of grade III oligodendroglioma (2015) Cancer Management and Research, 7, pp. 213-223. Cited 12 times. 12) https://www.scopus.com/inward/record.uri?eid=2-s2.0-84938408646&doi=10.2147%2fCMAR.S56975&partnerID=40&md5=d28197d30c4c235fe9146fbb14a39e5d DOI: 10.2147/CMAR.S56975 Document Type: Article Publication Stage: Final Access Type: Open Access Source: Scopus 13) Berzero, G., Stefano, A.L.D., Dehais, C., Sanson, M., Gaviani, P., Silvani, A., Salmaggi, A., Vitali, P., Diamanti, L., Baldanti, F., Farina, L.M., Ceroni, M., Marchioni, E. Herpes simplex encephalitis in glioma patients: A challenging diagnosis (2015) Journal of Neurology, Neurosurgery and Psychiatry, 86 (4), pp. 374-377. Cited 8 times. 13) https://www.scopus.com/inward/record.uri?eid=2-s2.0-84925345718&doi=10.1136%2fjnnp-2013-307198&partnerID=40&md5=83c744facaf456f85035ab743d086e43 DOI: 10.1136/jnnp-2013-307198 Document Type: Article Publication Stage: Final Source: Scopus 14) Lucchiari, C., Botturi, A., Silvani, A., Lamperti, E., Gaviani, P., Innocenti, A., Finocchiaro, C.Y., Masiero, M., Pravettoni, G. Cognitive strategies and quality of life of patients with high-grade glioma (2015) Supportive Care in Cancer, 23 (12), pp. 3427-3435. Cited 11 times. 14) https://www.scopus.com/inward/record.uri?eid=2-s2.0-84945468148&doi=10.1007%2fs00520-015-2691-z&partnerID=40&md5=8658422bdbcfe6b6426d2e2f89ac447c DOI: 10.1007/s00520-015-2691-z Document Type: Article Publication Stage: Final Source: Scopus 15) Silvani, A., Gaviani, P., DiMeco, F. Neoplastic disorders (2015) Prognosis of Neurological Diseases, pp. 331-348. 15) https://www.scopus.com/inward/record.uri?eid=2-s2.0-85028616206&doi=10.1007%2f978-88-470-5755-5_25&partnerID=40&md5=32c3dd0aed13d7a0a7476fe250d33b9c DOI: 10.1007/978-88-470-5755-5_25 Terms and conditions Privacy policy Copyright © 2020 Elsevier B.V. All rights reserved. Scopus® is a registered trademark of Elsevier B.V. Document Type: Book Chapter Publication Stage: Final Source: Scopus 16) Simonetti, G., Gaviani, P., Innocenti, A., Botturi, A., Lamperti, E., Silvani, A. Update on treatment strategies for anaplastic glioma: A review of literature (2014) Neurological Sciences, 35 (7), pp. 977-981. Cited 12 times. 16) https://www.scopus.com/inward/record.uri?eid=2-s2.0-84903378742&doi=10.1007%2fs10072-014-1829-y&partnerID=40&md5=7a361d630ea0dfc5f651f6c440b4100b DOI: 10.1007/s10072-014-1829-y Document Type: Review Publication Stage: Final Source: Scopus 17) Simonetti, G., Trevisan, E., Silvani, A., Gaviani, P., Botturi, A., Lamperti, E., Beecher, D., Bertero, L., Bosa, C., Salmaggi, A. Safety of bevacizumab in patients with malignant gliomas: A systematic review (2014) Neurological Sciences, 35 (1), pp. 83-89. Cited 8 times. 17) https://www.scopus.com/inward/record.uri?eid=2-s2.0-84892672578&doi=10.1007%2fs10072-013-1583-6&partnerID=40&md5=d3c2d270d497d64196d6d0097592a623 DOI: 10.1007/s10072-013-1583-6 Document Type: Review Publication Stage: Final
Load more

Recommended publications
  • Solid Forms of Ortataxel Feste Formen Von Ortataxel Formes Solides D’Ortataxel
    (19) & (11) EP 2 080 764 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07D 493/04 (2006.01) A61K 31/357 (2006.01) 22.08.2012 Bulletin 2012/34 A61P 35/00 (2006.01) (21) Application number: 08000904.6 (22) Date of filing: 18.01.2008 (54) Solid forms of ortataxel Feste Formen von Ortataxel Formes solides d’ortataxel (84) Designated Contracting States: (74) Representative: Minoja, Fabrizio AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Bianchetti Bracco Minoja S.r.l. HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT Via Plinio, 63 RO SE SI SK TR 20129 Milano (IT) Designated Extension States: AL BA MK RS (56) References cited: WO-A-01/02407 WO-A-02/44161 (43) Date of publication of application: WO-A-2007/078050 US-A1- 2007 212 394 22.07.2009 Bulletin 2009/30 US-B1- 7 232 916 (73) Proprietor: INDENA S.p.A. • HENNENFENT K L ET AL: "NOVEL 20139 Milano (IT) FORMULATIONS OF TAXANES: A REVIEW. OLD WINE IN A NEW BOTTLE?" ANNALS OF (72) Inventors: ONCOLOGY,KLUWER, DORDRECHT, NL, vol. 17, • Ciceri, Daniele no. 5, 2006, pages 735-749, XP008065745 ISSN: 20139 Milano (IT) 0923-7534 • Sardone, Nicola • NICOLETTI MARIA INES ET AL: "IDN5109, a 20139 Milano (IT) taxane with oral bioavailability and potent • Gabetta, Bruno antitumor activity" CANCER RESEARCH, vol. 60, 20139 Milano (IT) no. 4, 15 February 2000 (2000-02-15), pages • Ricotti, Maurizio 842-846, XP002478136 ISSN: 0008-5472 20139 Milano (IT) Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations.
    [Show full text]
  • SPECTRUM PHARMACEUTICALS, INC. (Exact Name of Registrant As Specified in Its Charter)
    Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES AND EXCHANGE ACT OF 1934 Date of Report: July 20, 2007 SPECTRUM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-28782 93-0979187 (State or other Jurisdiction (Commission File Number) (IRS Employer of Incorporation) Identification Number) 157 Technology Drive Irvine, California 92618 (Address of principal (Zip Code) executive offices) (949) 788-6700 (Registrant’s telephone number, including area code) N/A (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) TABLE OF CONTENTS Item 1.01 Entry Into Material Definitive Agreement. Item 8.01 Other Events. Item 9.01 Financial Statements and Exhibits. SIGNATURES EXHIBIT INDEX EXHIBIT 99.1 EXHIBIT 99.2 Table of Contents Item 1.01 Entry Into Material Definitive Agreement. On July 20, 2007, Spectrum Pharmaceuticals, Inc. (the “Company”) entered into a world-wide license agreement (the “License Agreement”) with Indena S.p.A., a Italian company (“Indena”), for ortataxel, a third-generation taxane classified as a new chemical entity that has demonstrated clinical activity in taxane-refractory tumors, effective as of July 17, 2007.
    [Show full text]
  • Tanibirumab (CUI C3490677) Add to Cart
    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
    [Show full text]
  • WO 2015/042414 Al 26 March 2015 (26.03.2015) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/042414 Al 26 March 2015 (26.03.2015) P O P C T (51) International Patent Classification: (74) Agents: ABELLEIRA, Susan, M. et al; Hamilton, Brook, C07D 401/14 (2006.01) C07D 417/12 (2006.01) Smith & Reynolds, P.C., 530 Virginia Rd, P.O. Box 9133, C07D 213/73 (2006.01) C07D 419/12 (2006.01) Concord, MA 01742-9133 (US). C07D 401/12 (2006.01) A61K 31/433 (2006.01) (81) Designated States (unless otherwise indicated, for every C07D 413/12 (2006.01) A61P 35/00 (2006.01) kind of national protection available): AE, AG, AL, AM, (21) International Application Number: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, PCT/US2014/056580 BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 19 September 2014 (19.09.2014) KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, (25) Filing Language: English MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (26) Publication Language: English SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (30) Priority Data: TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • Modifications to the Harmonized Tariff Schedule of the United States To
    U.S. International Trade Commission COMMISSIONERS Shara L. Aranoff, Chairman Daniel R. Pearson, Vice Chairman Deanna Tanner Okun Charlotte R. Lane Irving A. Williamson Dean A. Pinkert Address all communications to Secretary to the Commission United States International Trade Commission Washington, DC 20436 U.S. International Trade Commission Washington, DC 20436 www.usitc.gov Modifications to the Harmonized Tariff Schedule of the United States to Implement the Dominican Republic- Central America-United States Free Trade Agreement With Respect to Costa Rica Publication 4038 December 2008 (This page is intentionally blank) Pursuant to the letter of request from the United States Trade Representative of December 18, 2008, set forth in the Appendix hereto, and pursuant to section 1207(a) of the Omnibus Trade and Competitiveness Act, the Commission is publishing the following modifications to the Harmonized Tariff Schedule of the United States (HTS) to implement the Dominican Republic- Central America-United States Free Trade Agreement, as approved in the Dominican Republic-Central America- United States Free Trade Agreement Implementation Act, with respect to Costa Rica. (This page is intentionally blank) Annex I Effective with respect to goods that are entered, or withdrawn from warehouse for consumption, on or after January 1, 2009, the Harmonized Tariff Schedule of the United States (HTS) is modified as provided herein, with bracketed matter included to assist in the understanding of proclaimed modifications. The following supersedes matter now in the HTS. (1). General note 4 is modified as follows: (a). by deleting from subdivision (a) the following country from the enumeration of independent beneficiary developing countries: Costa Rica (b).
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,911,786 B2 Desai Et Al
    US00891. 1786B2 (12) United States Patent (10) Patent No.: US 8,911,786 B2 Desai et al. (45) Date of Patent: Dec. 16, 2014 (54) NANOPARTICLE COMPRISING RAPAMYCIN A61K 45/06 (2013.01); A61K 47/42 (2013.01); AND ALBUMINAS ANTICANCERAGENT A61N 5/10 (2013.01); A61N 7700 (2013.01) (75) Inventors: Neil P. Desai, Los Angeles, CA (US); USPC ............ 424/491; 424/489: 424/490; 424/500 Patrick Soon-Shiong, Los Angeles, CA (58) Field of Classification Search (US); Vuong Trieu, Calabasas, CA (US) USPC .......... 424/465-489, 490, 491, 500: 514/19.3 See application file for complete search history. (73) Assignee: Abraxis Bioscience, LLC, Los Angeles, CA (US) (56) References Cited (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S. PATENT DOCUMENTS U.S.C. 154(b) by 344 days. 5,206,018 A * 4/1993 Sehgal et al. ................. 424,122 5,362.478 A 11/1994 Desai et al. (21) Appl. No.: 12/530,188 5.439,686 A 8, 1995 Desai et al. 5,498.421 A 3, 1996 Grinstaffet al. (22) PCT Filed: Mar. 7, 2008 5,505,932 A 4/1996 Grinstaffet al. 5,508,021 A 4/1996 Grinstaffet al. (86). PCT No.: PCT/US2O08/OO3O96 5,512,268 A 4/1996 Grinstaffet al. 5,540,931 A 7/1996 Hewitt et al. S371 (c)(1), 5,560,933 A 10/1996 Soon-Shiong et al. (2), (4) Date: Mar. 4, 2010 5,635,207 A 6/1997 Grinstaffet al. 5,639,473 A 6/1997 Grinstaffet al.
    [Show full text]
  • I Regulations
    23.2.2007 EN Official Journal of the European Union L 56/1 I (Acts adopted under the EC Treaty/Euratom Treaty whose publication is obligatory) REGULATIONS COUNCIL REGULATION (EC) No 129/2007 of 12 February 2007 providing for duty-free treatment for specified pharmaceutical active ingredients bearing an ‘international non-proprietary name’ (INN) from the World Health Organisation and specified products used for the manufacture of finished pharmaceuticals and amending Annex I to Regulation (EEC) No 2658/87 THE COUNCIL OF THE EUROPEAN UNION, (4) In the course of three such reviews it was concluded that a certain number of additional INNs and intermediates used for production and manufacture of finished pharmaceu- ticals should be granted duty-free treatment, that certain of Having regard to the Treaty establishing the European Commu- these intermediates should be transferred to the list of INNs, nity, and in particular Article 133 thereof, and that the list of specified prefixes and suffixes for salts, esters or hydrates of INNs should be expanded. Having regard to the proposal from the Commission, (5) Council Regulation (EEC) No 2658/87 of 23 July 1987 on the tariff and statistical nomenclature and on the Common Customs Tariff (1) established the Combined Nomenclature Whereas: (CN) and set out the conventional duty rates of the Common Customs Tariff. (1) In the course of the Uruguay Round negotiations, the Community and a number of countries agreed that duty- (6) Regulation (EEC) No 2658/87 should therefore be amended free treatment should be granted to pharmaceutical accordingly, products falling within the Harmonised System (HS) Chapter 30 and HS headings 2936, 2937, 2939 and 2941 as well as to designated pharmaceutical active HAS ADOPTED THIS REGULATION: ingredients bearing an ‘international non-proprietary name’ (INN) from the World Health Organisation, specified salts, esters or hydrates of such INNs, and designated inter- Article 1 mediates used for the production and manufacture of finished products.
    [Show full text]
  • REVIEW Taxanes: Promising Anti-Cancer Drugs
    Taxanes: Promising Anti-Cancer Drugs REVIEW Taxanes: Promising Anti-Cancer Drugs Nilufer Jasmine Selimah Fauzee1, Zhi Dong2, Ya-lan Wang1* Abstract Taxanes are amongst the most promising antitumor agents available at hand today, of increasing importance in Asia given that cancer is now one of the major public health problems which needs to be dealt urgently for the benefit of affected patients. Several ongoing experimental and clinical trials have supported the fact that even with their side effects and poor solubilities, taxanes are still the first lines of treatment chosen for breast, ovary, lung and other metastatic cancers. Prolonging the life of cancer patients is the main aim of all researchers, scientists, pharmaceutical companies and clinicians; therefore this review emphasizes the mechanisms of action of taxanes and how they can play an important role in palliative treatment if not applied for curative purposes, hence being considered a boon for cancer management. Keywords: Taxanes - Taxol - Taxotere - cancer chemotherapy Asian Pacific J Cancer Prev, 12, 837-851 Introduction is of tremendous eagerness in the cancer field. So, here we have tried to underline their mechanism of action Taxanes are the most recently solicited chemotherapeutic under the rationale of their use and current development drugs of our era. During the past decades, these unique in oncology. hydrophobic mitotic inhibitors have been thoroughly investigated through numerous experimental and clinical Taxanes - Their Saga trials which have brought hope in breast, ovarian, lung, prostate (Tannock et al., 2004; Khan et al., 2003), Taxanes are remarkable cytotoxic diterpenes derived pancreas, gastric (Cosimo et al., 2003; Roth and Ajani, from natural products as described above.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr
    US008158152B2 (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr. 17, 2012 (54) LYOPHILIZATION PROCESS AND 6,884,422 B1 4/2005 Liu et al. PRODUCTS OBTANED THEREBY 6,900, 184 B2 5/2005 Cohen et al. 2002fOO 10357 A1 1/2002 Stogniew etal. 2002/009 1270 A1 7, 2002 Wu et al. (75) Inventor: Nageswara R. Palepu. Mill Creek, WA 2002/0143038 A1 10/2002 Bandyopadhyay et al. (US) 2002fO155097 A1 10, 2002 Te 2003, OO68416 A1 4/2003 Burgess et al. 2003/0077321 A1 4/2003 Kiel et al. (73) Assignee: SciDose LLC, Amherst, MA (US) 2003, OO82236 A1 5/2003 Mathiowitz et al. 2003/0096378 A1 5/2003 Qiu et al. (*) Notice: Subject to any disclaimer, the term of this 2003/OO96797 A1 5/2003 Stogniew et al. patent is extended or adjusted under 35 2003.01.1331.6 A1 6/2003 Kaisheva et al. U.S.C. 154(b) by 1560 days. 2003. O191157 A1 10, 2003 Doen 2003/0202978 A1 10, 2003 Maa et al. 2003/0211042 A1 11/2003 Evans (21) Appl. No.: 11/282,507 2003/0229027 A1 12/2003 Eissens et al. 2004.0005351 A1 1/2004 Kwon (22) Filed: Nov. 18, 2005 2004/0042971 A1 3/2004 Truong-Le et al. 2004/0042972 A1 3/2004 Truong-Le et al. (65) Prior Publication Data 2004.0043042 A1 3/2004 Johnson et al. 2004/OO57927 A1 3/2004 Warne et al. US 2007/O116729 A1 May 24, 2007 2004, OO63792 A1 4/2004 Khera et al.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,835,443 B2 Kawasaki Et Al
    USOO8835443B2 (12) United States Patent (10) Patent No.: US 8,835,443 B2 Kawasaki et al. (45) Date of Patent: *Sep. 16, 2014 (54) PYRIMIDINE COMPOUND AND MEDICAL (56) References Cited USE THEREOF U.S. PATENT DOCUMENTS (75) Inventors: Hisashi Kawasaki. Takatsuki (JP); 3,139,432 A 6/1964 Scarborough Hiroyuki Abe, Takatsuki (JP); Kazuhide 2004/O138285 A1 7, 2004 Okazaki Hayakawa, Takatsuki (JP); Tetsuya Iida, Takatsuki (JP); Shinichi Kikuchi, FOREIGN PATENT DOCUMENTS Takatsuki (JP); Takayuki Yamaguchi, Takatsuki (JP); Toyomichi Nanayama, A s A. 38: Takatsuki (JP); Hironori Kurachi, JP HO6-502152. A 3, 1994 Takatsuki (JP); Masahiro Tamaru, JP 2002-532414 T 10, 2002 Takatsuki (JP); Yoshikazu Hori, E. 5833. o I 1939: Takatsuki (JP); Mitsuru Takahashi, JP 2005ss4381 T 10, 2002 Takatsuki (JP); Takayuki Yoshida, JP 2002-332247 A 11, 2002 Yokohama (JP); Toshiyuki Sakai, Kyoto JP 2003-504401 T 2, 2003 (JP) JP 2004-504294 T 2, 2004 WO WOOO/35435 A1 6, 2000 WO WOOO/35436 A2 6, 2000 (73) Assignee: Japan Tobacco Inc., Tokyo (JP) WO WOOOf 40235 A2 7, 2000 WO WOOOf 40237 A1 T 2000 (*) Notice: Subject to any disclaimer, the term of this WO WOO1,05393 A2 1, 2001 patent is extended or adjusted under 35 W W 9:32, A. 38: U.S.C. 154(b) by 631 days. WO WOO2,06520 A1 1/2002 This patent is Subject to a terminal dis- (Continued) claimer. OTHER PUBLICATIONS (21) Appl. No.: 12/626,443 West, Anthony R., Solid State Chemistry and Its Applications, Wiley, New York, 1988, 358.* (22) Filed: Nov. 25, 2009 (Continued) (65) Prior Publication Data Primary Examiner — Erich A Leeser US 2010/O240613 A1 Sep.
    [Show full text]
  • Ep 3067054 A1
    (19) TZZ¥ZZ_T (11) EP 3 067 054 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 14.09.2016 Bulletin 2016/37 A61K 31/505 (2006.01) A61K 31/55 (2006.01) A61K 38/17 (2006.01) A61P 35/00 (2006.01) (21) Application number: 16156278.0 (22) Date of filing: 10.09.2008 (84) Designated Contracting States: • MIKULE, Keith AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Cambridge, MA Massachusetts 02139 (US) HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT • LI, Youzhi RO SE SI SK TR Westwood, MA 02090 (US) (30) Priority: 10.09.2007 US 971144 P (74) Representative: Finnie, Isobel Lara 13.12.2007 US 13372 Haseltine Lake LLP Lincoln House, 5th Floor (62) Document number(s) of the earlier application(s) in 300 High Holborn accordance with Art. 76 EPC: London WC1V 7JH (GB) 08830633.7 / 2 200 431 Remarks: (71) Applicant: Boston Biomedical, Inc. This application was filed on 18-02-2016 as a Cambridge, MA 02139 (US) divisional application to the application mentioned under INID code 62. (72) Inventors: • LI, Chiang, Jia Cambridge, MA Massachusetts 02141 (US) (54) NOVEL COMPOSITIONS AND METHODS FOR CANCER TREATMENT (57) The present invention relates to the composition and methods of use of Stat3 pathway inhibitors or cancer stem cell inhibitors in combination treatment of cancer. EP 3 067 054 A1 Printed by Jouve, 75001 PARIS (FR) EP 3 067 054 A1 Description REFERENCE TO RELATED APPLICATIONS 5 [0001] This application claims priority to and the benefit of U.S.
    [Show full text]
  • Genetic Toxicity Mini-Adverse Outcome Pathways (Mini-Aops)
    Genetic Toxicology Mini-Adverse Outcome Pathways (mini-AOPs) Azeddine Elhajouji March 22, 2018 Outline ❖ Introduction to AOP ❖ Mode of action and the need for mini-AOPs concept ❖ Mini-AOPs in genetic Toxicology ❖ Examples of mini-AOPs 2 ADVERSE OUTCOME PATHWAYS (AOP) • An Adverse Outcome Pathway (AOP) is a structured representation of biological events leading to adverse effects that is considered relevant to risk assessment. • The AOP links in a linear way existing knowledge along a pathway of causally connected key events (KE) between 2 points – a molecular initiating event (MIE) and an adverse outcome (AO). • The events occur at levels of biological organisation relevant to risk assessment e.g. molecular, cellular, tissue/organ, organism and/or population. • The linkage between the events is described by key event relationships (KERs) that describe the scientifically established causal relationship between the chain of key events. 3 ADVERSE OUTCOME PATHWAYS Molecular Cellular Organ Organism Population Ref: Ankley et al. (2010) Environ. Toxicol. Chem. 29: 730-741 KER1 KER2 KER3 KER4 MIE KE1 KE2 KE3 AO 4 “THE NEED FOR mini-AOPs CONCEPT” BETTER UNDERSTANDING OF MOA positive in standard gene mutagen what is the MOA mammalian clastogen leading to the GeneTox assay aneugen genotoxic outcome? • genetox assays good for hazard identification • not designed to provide detailed mechanistic information • do not identify molecular target • have often unclear structure activity relationship information • are not designed to provide dose-response information 5 WHY MINI-AOP AND NOT AOP? Exposure Exposure Molecular Organelle/ Cellular Tissue Organ Individual Population Source Initiating Molecular Effects Effects Effects Effects Effects Event Effects Toxicity Pathway (mini-AOP) Adverse Outcome Pathway • In vitro cellular effects can be more easily measured – More information available – Easier to hit dose-response relationships – Easier to address data gaps • Tissue effects often a combination of different cellular effects • Adverse health outcomes (i.e.
    [Show full text]